A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PF / progression-free

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PF  (>> Co-occurring Abbreviation)
Long Form:   progression-free
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. CAR, ICER, LY, QALY
2020 Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system. aTNBC, BPHS, ICER
2020 Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. ICUR, PP, PS, PSA, QALY
2019 Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. ALK, CNS, ICER, NSCLC, PP, QALYs, WTP
2018 Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective. ASCT, BV, cHL, LYs, QALYs
2017 Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. AE, ICER, irAE, PD-L1, QALY
2017 The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. ALK, PP, PSA, QALYs
2015 Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). RCC
2015 Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. BSC, EQ-5D, GIST, GLMM, ITT
10  2013 Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. EQ-VAS, HRQoL, NSCLC, PD
11  2012 Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. ---
12  2009 Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. Bt, MI, OS, Pa
13  2009 Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Ge, OS, OXA
14  2009 Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. IMRT, NPC
15  2007 Early stopping designs based on progression-free survival at an early time point in the initial cohort. ---
16  2002 Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. CRs, DCs, Id, Id-KLH, PR